One Million and Counting . . . in Support of Bladder Cancer Research
July 15th 2014When my late husband John and I started the Bladder Cancer Advocacy Network (BCAN) in 2005, our goal was not only to raise awareness about bladder cancer, but to change the landscape for this disease by funding research to discover new treatments that will save lives.
When Their Loved One Has Advanced Cancer, Caregivers Welcome Early Support
July 11th 2014Researchers from the nursing school at Case Western Reserve University have found caregivers of terminal cancer patients reported a high degree of satisfaction when they had a team available to them through difficult decisions and end-of-life treatment for their loved one.
Managing Side Effects of Androgen-Deprivation Therapy Increasingly Important
July 9th 2014Androgen-deprivation therapy (ADT) is a mainstay of treatment for prostate cancer in a number of settings, so managing its side effects is becoming increasingly important for urologists and oncology practitioners in collaboration with primary care physicians.
MRI-Guided Ultrasound Relieves Pain of Bone Metastases
July 8th 2014An approach using heat to alleviate the pain commonly associated with bone metastases has proven to be safe and effective in a multicenter phase III clinical trial, yielding a 64% response rate based on self-reported pain scores among patients receiving the noninvasive intervention.
New Oral Agent Found Effective in Preventing Muscle Wasting in NSCLC
July 1st 2014The results of two phase III trials reported at the 2014 MASCC/ISOO International Symposium on Supportive Care in Cancer have found that enobosarm, a first-in-class, nonsteroidal, oral selective androgen receptor modulator (SARM), led to an increase in lean body mass (LBM) compared with a decline in LBM observed with placebo for patients with non-small cell lung cancer (NSCLC).
Oral Netupitant-Palonestron Combination Offers Simpler Approach to Antiemesis Treatment
June 28th 2014A treatment intended to control chemotherapy-induced nausea and vomiting (CINV) that combines netupitant and palonosetron (NEPA) in a single capsule resulted in improved complete response rates (from 0 to 120 hours) when compared with oral palonosetron alone, according to research presented at the 2014 MASCC/ISOO International Symposium on Supportive Care in Cancer.
Docetaxel Associated With Intoxication, FDA Warns
June 20th 2014The FDA has issued a drug safety communication regarding the risk of intoxication with the intravenous ethanol-containing chemotherapy docetaxel. The drug is marketed as generic docetaxel and under the brand names Taxotere, Docefrez, and Docetaxel Injection.
For Breast Cancer Patients at Known BRCA Risk, a Role for Testing Prior to Surgery
June 17th 2014The majority of women with breast cancer who undergo the recommended genetic testing for BRCA1/2 mutations and test positive prior to undergoing surgery will change their surgical plan to include a more extensive procedure, a new study reports.
Survivorship Now Linked to Higher Medical Costs and Productivity Losses
June 16th 2014Cancer survivors (defined as people with a history of a cancer diagnosis) represent 4.6% of the U.S. population. The number of survivors is projected to increase at least 30% during the next ten years, and will likely reach 18 million people in the U.S.
CLL-Current and Emerging Therapies
June 12th 2014Please join us for our upcoming telephone/web education program, CLL- Current and Emerging Therapies on, Wednesday, June 18, 2014 1:00-2:30 pm EST featuring Thomas Kipps, MD, Deputy Director for Research at the University of California Moores Cancer Center.